Previous studies indicate that AHRR, a basic helix-loophelix/Per-ARNT-Sim (bHLH/PAS) family transcription factor, is transcriptionally regulated through activation of the AhR pathway. 12, 13 Tobacco smoke contains numerous agonists of AhR signaling 14 and persistent activation of the AhR signaling pathway has been hypothesized to contribute to atherogenesis. [15] [16] [17] [18] Although there is currently no known role of AHRR in atherogenesis, recent studies implicate upregulation of AHRR expression in monocyte-to-macrophage differentiation 19 and suppression of anti-inflammation. 13 We hypothesized that altered AHRR methylation levels in CD14+ monocytes, a cell type sensitive to cigarette smoking 20 and involved in atherogenesis, 21, 22 might provide a biological link between smoking and atherosclerotic plaque formation. Therefore, we integrated methylation profiles of CpG sites within 150 kb of AHRR (measured using the Illumina 450K array) in primary CD14+ monocytes with smoking status and ultrasound-measured carotid plaque scores from 1256 participants of the MultiEthnic Study of Atherosclerosis (MESA) 23 and sought replication in the Pathobiological Determinants of Atherosclerosis in Youth Study (PDAY, n=141). 24 To look for potential functional effects of smoking-associated AHRR methylation, we incorporated histone modification data in monocytes from the Encyclopedia of DNA Elements (ENCODE) 25 and Blueprint of Haematopoietic Epigenomes (BLUEPRINT) 26 projects, and gene expression measured in monocytes from a subset of the population (n=373) using RNA sequencing. Methylation and gene expression results were validated in independent monocyte samples using reduced representation bisulfite sequencing (RRBS, n=4) and real-time polymerase chain reaction (n=10).
Methods

Study Population
The MESA was designed to investigate the prevalence, correlates, and progression of subclinical CVD in a population cohort of 6814 participants. Since its inception in 2000, 5 clinic visits collected extensive clinical, sociodemographic, lifestyle, behavior, laboratory, nutrition, and medication data. 23 The present analysis is primarily based on analyses of purified monocyte samples from the April 2010 to February 2012 examination (examination 5) of 1264 randomly selected MESA participants from 4 MESA field centers (Baltimore, MD; Forsyth County, NC; New York, NY; and St. Paul, MN). The study protocol was approved by the Institutional Review Board at each site. All participants signed informed consent.
Data Collection
Smoking status, average number of cigarettes smoked per day, age of smoking cessation, and pack-years of cigarette smoking were assessed via standard American Thoracic Society questionnaire items. 27 Participants who reported smoking <100 cigarettes in their lifetimes were classified as never smokers. Among participants who reported smoking >100 cigarettes in their lifetime, those who reported smoking during the last 30 days were classified as current smokers and those who did not were classified as former smokers. Pack-years of cigarette smoking were calculated from age of starting to quitting (or current age among current smokers)×(cigarettes per day/20). Urinary cotinine levels were measured via immunoassay (Immulite 2000 Nicotine Metabolite Assay; Diagnostic Products Corp, Los Angeles, CA). 28 To obtain carotid artery plaque scores, readers adjudicated carotid plaque presence or absence, defined as a focal abnormal wall thickness (carotid intima-media thickness >1.5 mm) or a focal thickening of >50% of the surrounding intima-media thickness, as reported previously. 29, 30 Presence or absence of plaque acoustic shadowing was recorded. A total plaque score (range, 0-12) was calculated to describe carotid plaque burden. One point per plaque was allocated for the near and far walls of each segment (common carotid artery, bulb, and internal carotid artery) of each carotid artery that was interrogated. For carotid plaque presence, intrareader reproducibility was excellent (per reader κ=0.82-1.0, overall κ=0.83, 95% confidence interval, 0.70-0.96), as was inter-reader reproducibility (κ=0.89; 95% confidence interval, 0.72-1.00). 31 Weight was measured with a Detecto Platform Balance Scale to the nearest 0.5 kg. Height was measured with a stadiometer (Accu-Hite Measure Device with level bubble) to the nearest 0.1 cm. Body mass index was defined as weight in kg divided by square of height in meters. Type 2 diabetes mellitus was defined as fasting glucose ≥6.99 mmol/L (≥126 mg/dL) or use of hypoglycemic medication. Fasting serum glucose was measured by rate reflectance spectrophotometry using thin film adaptation of the glucose oxidase method on the Vitros analyzer (Johnson & Johnson Clinical Diagnostics, Rochester, NY). To achieve consistency of the serum glucose assay over examinations, 200 samples were reanalyzed and then recalibrated the original observations. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation. Resting blood pressure was measured 3× in the seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, FL). The average of the last 2 measurements was used in analysis. Hypertension was assessed using the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNV VI) criteria (systolic pressure ≥140 mm Hg, diastolic pressure ≥90 mm Hg, or current use of antihypertensive medication).
Purification of Monocytes
Monocytes were isolated with anti-CD14 monoclonal antibodycoated magnetic beads, using AutoMACs automated magnetic separation unit (Miltenyi Biotec, Bergisch Gladbach, Germany). Initially, flow cytometry analysis of 18 monocyte samples collected from all 4 MESA field centers was performed to assess the cell purification quality across the laboratories and technicians. The purity was >90% for all samples (see Data Supplement for details).
DNA/RNA Extraction
DNA and RNA were isolated from samples simultaneously using the AllPrep DNA/RNA Mini Kit (Qiagen Inc., Hilden, Germany; see Data Supplement for details).
Methylation Quantification
Illumina HumanMethylation450 BeadChips and HiScan reader were used to perform the epigenome-wide methylation analysis (see Data Supplement for details). This methylation data have been deposited in the NCBI Gene Expression Omnibus and are accessible through GEO Series accession number (GSE56046).
Quality Control and Preprocessing of Microarray Data
Data preprocessing and quality control analyses were performed in R (http://www.r-project.org/) using Bioconductor (http://www.bioconductor.org/) packages (Detailed Methods in the Data Supplement). The Illumina HumanMethylation450 BeadChip included probes for 485K CpG sites. Of these CpG sites, 484 817 passed the quality control elimination criteria including detected methylation levels <90% of MESA samples using a detection P value cutoff of 0.05 or overlap with a repetitive element or region.
To estimate residual sample contamination for data analysis, we generated separate enrichment scores for neutrophils, B cells, T cells, monocytes, and natural killer cells. We implemented a Gene Set Enrichment Analysis 32 as previously described 33 to calculate the enrichment scores using the gene signature of each blood cell type from previously defined lists. 34 To remove technical error in methylation levels associated with batch effects across the multiple chips, positional effects of the sample on the chip, and residual sample contamination with nonmonocyte cell types, we adjusted methylation M values for chip, sample position on the chip, and estimated residual sample contamination with neutrophils, B cells, T cells, monocytes, and natural killer cells.
mRNA Quantification Using RNA Sequencing
A subset of 374 samples was randomly selected from the 1264 MESA monocyte samples for RNA sequencing of mRNA (see Data Supplement for details).
Association Analyses
The overall goal of the association analysis was to characterize associations between smoking and AHRR methylation and AHRR methylation and carotid plaque scores. Analyses were performed using the linear model (lm) function of the Stats package and the stepAIC function of the MASS package in R. Reported correlations (r) represent the partial Pearson product-moment correlation coefficient, after adjusting for covariates.
To identify methylation sites associated with smoking, we fit separate linear regression models with smoking status as a predictor of the M value for each CpG site genome wide that passed quality control. Covariates were age, sex, race/ethnicity, and study site. P values were adjusted for multiple testing using the q-value false discovery rate (FDR) method. 35 The FDR was calculated at the genome-wide level, including all 484 817 CpGs passing quality control, although only results from CpG sites within 150 kb of AHRR (542 CpGs) are presented.
To identify potential bimodal distributions, we calculated the kurtosis and skewness of the M-value distributions of the 542 probes investigated. Six probes (1.1%) were found to have strong negative kurtosis (kurtosis < −0.75) and some skewness (skewness < −0.3 or skewness >0.3), suggesting bimodal distributions. Although linear regression estimates are robust to the normality assumption in large samples, we next performed permutation testing with the 542 CpGs (H 0 : β=0, ie, no difference in current smoking versus never smoking) to ensure the validity of the linear regression results. The number of permutations was set to be 1000 for all CpGs, and for CpGs with P value < 0.10, we also ran 100 000 permutations. We found consistent permutation P values compared with the normal P values from the linear regression analysis for all probes, including the 6 probes with bimodal distributions. The correlation between the normal and permutation P values is 0.999, the correlation between the ranks based on the normal and permutation P values is also 0.999, and the sum of the absolute differences between the normal and permutation P values divided by the sum of the normal P values is 2% (0.02).
To characterize the association between AHRR methylation and carotid plaque levels, we fit separate linear regression models with the M-value for the 542 CpGs within 150 kb of AHRR as a predictor of carotid plaque scores (natural log [carotid plaque score+1]). Initial analysis covariates were age, sex, race/ethnicity, and study site. Secondary analyses adjusted for smoking status, the number of cigarettes per day, pack-years, traditional CVD risk factors (body mass index, LDL cholesterol, hypertension, and diabetes mellitus), and statin use.
Methylation of the most significantly differentially methylated CpG associated with smoking status and with carotid plaques scores (ie, cg05575921) was also investigated for association with nearby gene expression levels and genetic variants. We arbitrarily chose to investigate a large window (±1 Mb) surrounding the CpG to avoid missing any potential effects. For gene expression analysis, we fit separate linear regression models with the M-value as a predictor of mRNA expression for any autosomal gene within 1 Mb of the CpG. Covariates were age, sex, race/ethnicity, and study site. For analyses of nearby genetic variants, we fit separate linear regression models with single nucleotide polymorphisms located within 1 Mb as a predictor of the M-value in the MESA samples from white participants, including single nucleotide polymorphisms with a minor allele frequency >0.05 in the MESA samples from white participants. P values were adjusted for multiple testing using the q-value FDR method. 35 
Mediation Analysis
We performed mediation analysis to investigate the hypothesis that smoking may have an effect on atherosclerosis mediated through methylation alteration. We used structural equation modeling with bootstrapping as implemented in the R package lavaan 36 to estimate the indirect effects (mediated through methylation) of current smoking (cigarettes per day) and cumulative exposure (pack-years) on carotid plaque score in current and former smokers for the most significantly differentially methylated CpG associated with smoking status and with carotid plaques score.
Replication Study
Replication analysis for the most significantly differentially methylated CpG associated with smoking status and with carotid plaques score included samples from 141 men from the PDAY 24 (see Data Supplement for details). Tests for association between methylation measured in hepatic samples and the extent of fatty streaks observed in the right coronary arteries and the left halves of the aortas were performed using linear regression, including the following risk factors: age, race, lipids (high-density lipoprotein and non-high-density lipoprotein), body mass index, and glucose levels.
RRBS Methods and Differentially Methylated Region Identification
To investigate the relationship between smoking and CpG methylation not captured by microarray, RRBS libraries of CD14+ monocytes from 2 smokers and 2 nonsmokers were generated as previously described 37 with minor modifications (see Data Supplement). To identify genomic regions that are differentially methylated regions (DMRs) between smokers and nonsmokers, we used the method described in the study by Ziller et al. 38 Briefly, this method first uses the methylated and unmethylated counts to identify a set of dynamic CpGs, which are CpGs that are significantly differentially methylated between groups, using a model based on the β difference distribution. Next, it merges any dynamic CpGs whose genomic locations are within 500 bp into a set of CpG clusters. Finally, all clusters that are significantly differentially methylated between groups are retained as the final set of DMRs. We defined the DMR location as the region between the outermost CpGs in the cluster. We excluded any DMRs that had fewer than 5 CpGs with nonzero methylation counts, and we also excluded any DMRs that had an overall methylation difference of <10%.
Functional Characterization
Histone modifications in monocytes and monocyte-derived macrophages from BLUEPRINT 19 were downloaded from GEO (Series GSE58310), including H3K27ac and H3K4me1. Other histone modifications in monocytes from ENCODE 39 were downloaded through the UCSC browser, 25 including H3K4me1 (GEO accession GSM1003535), H3K4me3 (GEO accession GSM1003536), and H3K27me3 (GEO accession GSM1003564), which were produced by the Bernstein laboratory at the BROAD Institute.
Reverse Transcription Quantitative Polymerase Chain Reaction
Reverse transcription quantitative polymerase chain reaction was used for replication of gene expression in CD14+ monocytes from nonsmokers and smokers collected at the National Institute of Environmental Health Sciences Clinical Research Unit (see Data Supplement).
Results
The study population (n=1256 ; Table) was composed of 47% whites, 32% hispanics, and 21% blacks who were recruited from 4 different study sites across the United States, as previously described.
33
AHRR Methylation and Smoking
We identified 33 of 542 CpGs within 150 kb of AHRR whose degree of methylation was significantly associated with cigarette smoking at a genome-wide FDR threshold of 5% (P ranging 6.1×10 −134 to 2.5×10 −4
; Figure 1 ) in monocytes from 114 current smokers and 502 never smokers. Methylation of cg05575921 (chr5:373,378; hg19) within the AHRR gene body represented the most significantly (P=6.07×10 ) differentially methylated CpG. To explore the smoking-associated cg05575921 methylation in more detail, we examined the relationship between smoking history/status, the dosage of exposure, the level of urinary cotinine, and cg05575921 methylation. In agreement with the proposed reversibility of smoking-responsive cg05575921 methylation, 9 the average methylation measured in former smokers (mean β=0.79) was more similar to never smokers (mean β=0.83; Figure 2A ) than current smokers (mean β=0.59). Furthermore, we found that cg05575921 methylation was positively correlated with time since quitting in former smokers (partial correlation: r=0.35, P<2×10 −16 , Figure 2B ) and was negatively correlated with recent exposure measurements in current smokers, such as the average number of cigarettes smoked per day (r=−0.39, P=6.1×10 −5 ; Figure 2C ) and urinary cotinine levels (r=−0.43, P<9.09×10 −4 ; Figure 2D ), after adjusting for age, sex, race, and study site. Consistent with these findings, cg05575921 methylation was also significantly negatively correlated with cumulative exposure measured by pack-years in current smokers (r=−0.34, P=3.97×10 −4 ) and former smokers (r=−0.35, P<2×10 −16 ; Figure I in the Data Supplement).
AHRR Methylation and Carotid Plaque Scores
Among all investigated CpGs within 150 kb of AHRR, methylation profiles of 2 CpGs were associated with higher carotid plaque scores (cg05575921, P=3.08×10 −10 ; cg21161138, P=7.73×10 −8 ; Figure 3A) , both of which were also associated with smoking. Including both CpG methylation profiles in the same model did not find independent effects for these CpGs on carotid plaque score (methylation correlation=0.37).
Importantly, even after adjusting for statin use and traditional CVD risk factors, including body mass index, lowdensity lipoprotein cholesterol, hypertension, and diabetes mellitus, the CpG with methylation most strongly associated with carotid plaque score remained significant (cg05575921, r=−0.18, P=1.14×10 −9 , Figure 3B ). After additionally adjusting for smoking status, the effect of cg05575921 methylation on carotid plaque score remained significant (r=−0.13, P=2.2×10 −5 ). We then stratified by smoking status and found that the estimated effect of cg05575921 methylation was strongest among current smokers (r=−0.32, P=2.93×10 −3 ) and was attenuated in former smokers (r=−0.13, P=1.64×10 −3 ). No significant relationship was detected between AHRR methylation and carotid plaque score in never smokers (r=−0.03; P=0.46), likely because of the predominantly hypermethylated state of cg05575921 in never smokers, and the associated reduced variability of methylation in never smokers compared with current and former smokers.
In current and former smokers, the effect of cg05575921 methylation on carotid plaque score was further attenuated, but remained significant (P<0.05) after including selfreported pack-years and urinary cotinine levels in the model (Table I in the Data Supplement). Standardized effect estimates of cg05575921 methylation (β=−0.13, P=0.01) and pack-years (β=0.13, P=0.007) on carotid plaque score were similar in magnitude, each uniquely explaining ≈1% of the variance of carotid plaque score. The standardized effect size of cg05575921 methylation on carotid plaque score was similar in magnitude to the effect of low-density lipoprotein cholesterol on carotid plaque score (β=0.16, P=0.001), as shown in the full model results presented in the Table I in the Data Supplement.
Using mediation analysis to explore if methylation was intermediate in the association between smoking (pack-years and cigarettes per day) and higher carotid plaque score, we found that cg05575921 methylation significantly mediated 37% of the total effect of self-reported pack-years on carotid plaque score (indirect effect: β±SE, 0.25±0.06; P=3.1×10 −4 ) in current and former smokers, and 60% of the total effect of cigarettes per day on carotid plaque score (indirect effect: β±SE, 0.011±0.004; P=4.3×10 −3 ) in current smokers. We replicated both the associations of cg05575921 methylation (in hepatic cells) with smoking (P=0.002) and with subclinical atherosclerosis (extent of fatty streaks in the right Figure 1 . Cigarette smoking status is strongly associated with DNA methylation profiles of aryl hydrocarbon receptor repressor (AHRR) in monocytes from current smokers and never smokers. Regional association plot shows the significance (y axis: −log 10 P value; FDR genome-wide <0.05 colored red; FDR genome-wide ≥0.05 colored black) of the association between smoking status (114 current vs 502 never smokers) and methylation in CD14+ monocytes (542 CpGs within 150 kb of AHRR, measured using the Illumina 450K microarray). The blue horizontal line represents a Bonferroni corrected significance threshold (α=0.05) for the 542 CpGs examined. The genomic position (hg19) of AHRR relative to the CpGs is shown below the association plot (in blue). Regression covariates included age, sex, race, and study site. ) in current smokers. Regression covariates included age, sex, race, and study site.
coronary arteries and left halves of the aortas; P=0.002) measured at autopsy in biopsies from 141 young men (<35 years) from the PDAY study.
Functional Genomic Characterization of the cg05575921 Locus
Using RRBS to measure CpG methylation in non-MESA monocyte samples from 2 smokers and 2 nonsmokers, we recapitulated the association between smoking and methylation of cg05575921. In addition, RRBS revealed 7 adjacent (within 180 bp) CpGs not included on the Illumina 450K microarray, which displayed similar directional changes in methylation with smoking status, composing a smoking-associated DMR (Figure 4 ; Figure II in the Data Supplement).
The AHRR DMR (chr5:373,378-373,556 hg19) is located in a potential poised enhancer region, based on the presence of both activating (H3K27ac/H3K4me1) and repressive (H3K27me3) histone modifications in a monocyte sample (from ENCODE 25 ). This enhancer region seems to be strongly activated (based on the enrichment of histone marks H3K27ac/ H3K4me1) on monocyte differentiation to macrophage (from BLUEPRINT 19, 26 ; Figure 4 ).
DNA Methylation of cg05575921 and cis-Gene Expression
In a subset of the MESA monocyte samples with both RNA sequencing and methylation profiles (n=373, including 29 current smokers and 152 never smokers), cg05575921 methylation significantly (FDR<0.05) associated with mRNA expression of only 1 gene within 1 Mb, AHRR (r=−0.42, P=1.4×10 −17 , FDR=4.32×10 −15 ; Figure 5A ). Analysis stratified by smoking status revealed that AHRR expression was strongly upregulated in current smokers (P=3.29×10 −21 ; Figure IIIA in the Data Supplement), which was replicated using real-time polymerase chain reaction in a set of independent monocyte samples (P=0.003; Figure IIIB in the Data Supplement).
Next, we tested for associations between AHRR expression and carotid plaque score and found suggestive evidence, even in our small sample size of current smokers with RNAsequencing measurements, for a positive association between AHRR expression and carotid plaque score (r=0.53, P=0.07, n=21; Figure 5B ). Carotid plaque score was also positively associated with AHRR expression in former smokers (r=0.17, P=0.03, n=175), but not in never smokers (P>0.05; n=147).
Nearby genetic variants were also investigated for association with cg05575921 methylation; however, no significant (FDR<0.05) associations were observed with common genetic variants.
Discussion
Extending previous findings in other tissues, we found decreased methylation levels in human monocytes at the AHRR CpG cg05575921 is a significant biomarker of smoking. This finding is in line with several previous reports in other cell types. 6, 7, 11 Cg05575921 methylation seemed to be dosage dependent and at least partially reversible on smoking cessation. These results, along with other published reports, 7 indicate that methylation levels at cg05575921 represent a biomarker of effect that integrates both smoking dose and duration.
Importantly, we uncovered novel associations between smoking-responsive methylation of AHRR in monocytes and subclinical atherosclerosis in a large, multiethnic human cohort and replicated the association between subclinical atherosclerosis and AHRR methylation in hepatic cells from an independent cohort. These results suggest that smokingaltered methylation of AHRR in multiple cell types may represent a biomarker for the risk of atherosclerosis associated with smoking. A, Regional association plot shows the significance (y axis: log 10 P value) of the association between methylation (542 CpGs within 150 kb of AHRR measured in 1176 CD14+ monocyte samples) and ultrasound-measured carotid plaque score (ln[plaque score+1]). Two methylation profiles (cg05575921 and cg21161138, r=0.37) significantly associated with carotid plaque score (indicated as stars), based on a Bonferroni adjusted significance threshold for 542 CpGs (α=0.05; indicated by the blue horizontal line). CpGs with methylation associated with smoking (FDR genome-wide <0.05) are colored red. The genomic position (hg19) of AHRR relative to the CpGs is shown below the association plot (in blue). Regression covariates included age, sex, race, and study site. B, Forest plot shows the estimated effect size (x axis: β and 95% confidence interval) of cg05575921 methylation on carotid plaque score (overall and stratified by smoking status). Also shown are the sample size (n), the partial Pearson's correlation coefficient (Cor) between methylation and carotid plaque score, the unique variance (Rsq) of carotid plaque score explained by cg05575921 methylation, and the significance (P value). Regression covariates included age, sex, race, study site, BMI, LDL cholesterol, diabetes, hypertension, and statin use.
Our results also indicate that AHRR methylation could be a useful biomarker of atherosclerosis in addition to selfreported smoking exposure and other known CVD risk factors. For instance, in current and former smokers, AHRR methylation remained significantly associated with subclinical atherosclerosis even after adjustment for self-reported smoking exposure, urinary cotinine, and many other known CVD risk factors. However, longitudinal studies are necessary to confirm AHRR methylation as a predictor of atherosclerosis.
Genome-wide association studies have suggested that differential DNA methylation is often associated with expression changes of nearby genes. 33 Functionally, we found that reduced methylation levels at cg05575921, measured by microarray, were associated with upregulated AHRR mRNA expression in monocytes from 373 participants, measured using RNA sequencing, and in an independent sample using reverse transcription quantitative polymerase chain reaction. Combined with a recent report in lung tissue from 5 smokers and 5 nonsmokers found that smoking-associated methylation of AHRR was linked with increased AHRR expression (P=0.0047), 10 these results provide evidence that altered AHRR methylation profiles may mediate increased transcription of AHRR in smokers.
Previous studies indicate that AHRR is transcriptionally upregulated by activation of the AhR pathway. 12, 13 Interestingly, RRBS showed that the AHRR cg05575921 locus is located in a smoking-associated DMR, which seems to overlap an intragenic enhancer that is activated, accompanied by upregulation of AHRR expression, when monocytes differentiate into macrophages. 19 Taken together with the ability of DNA methylation profiles to predict enhancer activity, 40, 41 we hypothesize that smoking-induced AhR pathway activation drives methylation changes in the AHRR gene accompanied by histone modifications and enhancer activation, resulting in upregulation of AHRR expression in monocytes. Residual levels of altered methylation and enhancer activity at the cg05575921 Figure 4 . Functional genomic characterization of the smoking-and carotid plaque score-associated locus within aryl hydrocarbon receptor repressor (AHRR). Cg05575921 is located on chromosome 5p15.33 in an AHRR intron and a CpG island shore. Within 500 bp of cg05575921, the Illumina450 microarray captured 2 additional CpGs, both of which were associated with smoking in Multi-Ethnic Study of Atherosclerosis (MESA; FDR genome-wide <0.05). Fine mapping using reduced representation of bisulfite sequencing (RRBS) revealed a statistically significant (P=2.39×10 −5 ) differentially methylated region (DMR, brown bar, chr5:373,378-373,556 hg19) by smoking status, including cg05575921 and 7 other CpGs within 200 bp that were not included on the Illumina 450K microarray. RRBS was performed in non-MESA monocyte samples from 2 nonsmokers (shown in dark blue) and 2 current smokers (shown in red), with the resulting percent methylation detected for nearby CpGs shown on the y axis. This DMR overlaps potential functional features, including histone modifications indicative of an active enhancer (H3K27ac and H3K4me1) in monocyte-derived macrophages (Mf; from BLUEPRINT) and a poised enhancer (active: H3K4m1; repressed: H3K27m3) in a CD14+ monocyte sample (from ENCODE).
DMR in former smokers could partially explain why AHRR gene expression was previously reported to be upregulated in former smokers compared with never smokers even decades after smoking cessation. 42 The consequences of AHRR upregulation in monocytes are unclear, but given the potential role of AHRR in macrophage biology 19 and suppression of anti-inflammation, 13 upregulation of AHRR could plausibly alter the function of monocytes and macrophages in smokers. Although there is currently no known role for AHRR in atherogenesis, several studies have shown that activation of the AhR pathway promotes atherosclerosis. For instance, using in vitro and in vivo models in mice, Wu et al 18 demonstrated that AhR pathway activation with treatments, such as cigarette smoke extract or 2,3,7,8-tetrachlorodibenzo-pdioxin, increased expression of inflammatory markers in macrophages and were associated with the accumulation of lipids in macrophages and plaque formation. Vogel et al 43 showed that AhR pathway activation increased cytokine production and foam cell formation. A limitation of our study is it remains unclear if smoking-associated AHRR expression is causally related to atherogenesis or occurs in parallel to the AhR activation-related effects on plaque formation noted above. Mediation analysis results do not distinguish confounding from mediating effects; therefore, although we observe cg05575921 methylation significantly mediating the effect of pack-years on carotid plaque score, these results do not confirm biological mediation and should be interpreted with caution.
In conclusion, we identified smoking-responsive methylation profiles at the cg05575921 locus, which are associated with upregulated AHRR expression in monocytes and with subclinical atherosclerosis in a human population. Future functional studies are necessary to understand the potential role of AHRR in response to cigarette smoke and in atherogenesis. 
